About: http://webisa.webdatacommons.org/319911609

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	Currently approved PPAR-?? ligands such as rosiglitazone have been linked to side effects, including fluid retention, heart failure, and other cardiovascular events, raising questions regarding their safety [54].
http://www.w3.org/ns/prov#wasQuotedFrom	plos.org